Best Oncology Companies in Florida, United States
The 71 best Oncology companies in Florida, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NeoGenomics.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Florida
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | NeoGenomics Provider of cancer genetic diagnostic services | $446M | 65 mo ago | 2,100 2,100 → 1,793 (-15%) | — | — | — |
| 2 | Oragenics Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health | $87M | 34 mo ago | 5 | Alan Joslyn CEO & President | 123 patents Intranasal drug delivery systems for treating traumatic brain injury and concussion | 2 launchs |
| 3 | Blink Bio Develops technologies for targeted delivery of therapeutics | $59M | 83 mo ago | 8 | — | — | — |
| 4 | X-VAX Technology Developer of virus-based vaccines for treating herpes | $56M | 83 mo ago | 12 | — | — | — |
| 5 | TuHURA Biosciences Developer of immunotherapies for the treatment of cancer 42Funding top 20%Talent top 38%Moat top 39%Growth top 45% All 8 signals ▾Fundingtop 20% Talenttop 38% Moattop 39% Growthtop 45% Techbottom 47% Newsbottom 39% Globalbottom 36% Marketbottom 32% Funding: Raised $37.8M across 11 rounds · 11 rounds over 8 yrs (1.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $38M | 7 mo ago | — | Patricia Lawman Co-Founder | — | — |
| 6 | Xcovery Kinase inhibitors to treat non-small cell lung cancer | $38M | 133 mo ago | 18 | — | 53 patents Novel crystalline kinase inhibitor compounds for therapeutic use. | — |
| 7 | DermaSensor Developer of an AI-powered skin cancer detection device 64Funding top 25%News top 29%Innovation top 35%Growth top 35% All 12 signals ▾Fundingtop 25% Newstop 29% Innovationtop 35% Growthtop 35% AItop 35% Producttop 35% Moattop 37% Techtop 38% Patentstop 42% Talentbottom 49% Marketbottom 34% Globalbottom 33% Funding: Raised $35.8M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) News: 3 BI events in 12 mo (of 7 tracked, 3 types) · Top themes: Funding, Capital raise rank vs industry peers · Fliar Intelligence Index 64/100 | $36M | 8 mo ago | 24 | Cody Simmons CEO | 10 patents Non‑invasive optical detection of skin cancer via elastic scattering spectroscopy calibration. | — |
| 8 | Mirror Biologics Developer of next-generation immunotherapy products | $30M | 44 mo ago | 20 | Michael Har-Noy Founder & CEO | 34 patents Engineered artificial lymph node bioreactors for cancer immunotherapy and vaccine development | — |
| 9 | Vigilant Biosciences Point of care and lab solutions for detection of cancer | $30M | 96 mo ago | 26 | — | — | — |
| 10 | Enveric Developer of small-molecule therapeutics for the treatment of neuropsychiatric disorders 42Funding top 29%News top 30%Growth top 31%Talent bottom 49% All 9 signals ▾Fundingtop 29% Newstop 30% Growthtop 31% Talentbottom 49% Fin. healthbottom 42% Techbottom 38% Globalbottom 38% Marketbottom 36% Moatbottom 36% Funding: Raised $26.4M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) News: 15 BI events in 12 mo (of 35 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 2 mo ago | 25 | Joseph Tucker CEO | — | — |
| 11 | Imaging Diagnostic Systems Innovating non-invasive laser breast imaging technology for early detection | $25M | 310 mo ago | 4 | — | — | — |
| 12 | Intezyne Clinical-stage company developing drugs for the treatment of various tumor diseases | $19M | 104 mo ago | 4 | — | 190 patents Nanocarrier drug delivery systems and ruthenium‑based anticancer compounds | — |
| 13 | Syncromune Developer of therapeutic vaccines for the treatment of cancer | $14M | 18 mo ago | 13 | Eamonn Hobbs CEO | 11 patents Intratumoral tumor cell lysis devices delivering combinatorial immunotherapies for cancer treatment | — |
| 14 | Stem Synergy Biotechnology company discovering novel cancer therapeutics targeting fundamental mechanisms | $14M | 50 mo ago | 8 | Anthony Capobianco Co-Founder | — | — |
| 15 | VeriTeQ Medical device hardware and service provider with RFID implantable technology | $14M | 135 mo ago | 11 | Ken Shapiro CEO | — | — |
| 16 | Black Light Surgical Developer of a device for imaging diagnostics of cancer | $13M | 11 mo ago | 1 | — | — | — |
| 17 | Sensus Healthcare Medical device company specializing in non-invasive skin cancer and keloid treatments | $12M | 125 mo ago | 42 42 → 58 (+38%) | Joseph Sardano Chairman & CEO | 46 patents Patents concentrated in health & consumer products | — |
| 18 | AIM ImmunoTech Developer of drugs for various immune-related diseases and cancer | $10M | 82 mo ago | 185 | Thomas Equels CEO | 100 patents RNA‑based antivirals and vaccines targeting post‑viral syndromes and neuroinflammation | — |
| 19 | Modulation Therapeutics Developing innovative therapies targeting cancer and liver disease | $5M | 15 mo ago | — | Mark McLaughlin Co-Founder & EVP | — | — |
| 20 | QSAM Biosciences Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation | $4M | 64 mo ago | 4 | Douglas Baum CEO | — | — |
| 21 | Sun BioPharma Therapeutics for pancreatic cancer | $4M | 81 mo ago | 4 | — | — | — |
| 22 | BMRT Provider of devices for diagnosis of cancer | $3M | 31 mo ago | — | Lee Duke Co-Founder | — | 1 launch · 1 award |
| 23 | Mel-Mont Medical Developer of molecular screening devices for the early detection of infectious diseases | $3M | 6 mo ago | 4 | Frank Melendez Co-Founder & CEO | — | — |
| 24 | Myosin Therapeutics Developer of therapeutics for CNS-based disorders | $3M | 10 mo ago | 8 | Courtney Miller Co-Founder | — | — |
| 25 | Medite Developer of products for histology and cytology | $3M | 92 mo ago | 71 | — | — | — |
| 26 | NOK Therapeutics Developer of autologous natural killer (NK) cell therapies for cancer | $2M | 20 mo ago | — | Robert Lewis Co-Founder & CEO | — | — |
| 27 | MDNA Life Sciences Provider of genomic and molecular diagnostics based on the mitochondrial genome | $1M | 89 mo ago | 8 | — | — | — |
| 28 | Vector Vitale Developer of bio-molecule-based therapeutics for the treatment of oncology and other degenerative diseases | $1M | 49 mo ago | 4 | Victor Vedovato Managing Director | 103 patents Anti‑aging nutraceuticals and pharma compositions targeting homeostasis, inflammation, and viral defense | — |
| 29 | NovelStem Developer of stem cell-based diagnostics to predict patients resistance to cancer chemotherapies | $700K | 122 mo ago | 15 | Mitchell Rubenstein Founder & CEO | — | — |
| 30 | Cvergenx Genomic informatics company personalizing radiation therapy with precision genomic radiation therapy platform | $616K | 126 mo ago | 3 | — | 10 patents Genomics-driven personalized radiation therapy planning and dosing for head‑and‑neck cancers | — |
| 31 | BioCurity Developer of nanoparticle-based drugs for cancer treatment | $556K | 36 mo ago | 1 | Cheryl Baker Director and Scientific Founder | 9 patents Cerium oxide nanoparticle radioprotective formulations for cancer radiation therapy and skin protection | — |
| 32 | Aurora BioPharma CAR T cell based immunotherapies for solid cancers. | $440K | 113 mo ago | — | Robert Brooks CEO | — | — |
| 33 | Diverse Biotech Developer of therapeutics for treating cancer | $338K | 81 mo ago | 6 | — | 41 patents Cannabinoid‑beta‑lactam conjugate therapeutics for antiviral and anti‑cancer applications | — |
| 34 | Venn Therapeutics Developer of immunotherapies for treating cancer | $225K | 81 mo ago | 6 | Sam Shrivastava Founder & CEO | — | — |
| 35 | Epigenetix Pioneering epigenetic therapies for cancer, targeting novel drug discovery and development | $167K | 117 mo ago | — | Joseph Collard Cofounder CEO | 18 patents Pharmaceutical benzimidazole compounds and their controlled‑release formulations | — |
| 36 | PanAm HIFU Foreign language education and research institute at a Chinese university | $150K | 142 mo ago | — | Ronald Wheeler Managing Director | — | — |
Top 12 Oncology companies in Florida
#1
Public · Naples, Florida · founded 1994 · 25 employees$26.4Mraised▾
Developer of small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company leverages discovery and development platform Psybrary developing combination therapies with chemotherapeutic agents and immunotherapies for anxiety, depression, and addiction disorders.
- Apr 2026Post IPO$5M
- Apr 2023Post IPO$12.8M
- Aug 2022Post IPO$8.6M
#2
Public · Tampa, Florida · founded 1996$37.8Mraised▾
Developer of immunotherapies for the treatment of cancer. The company is focused on developing novel personalized cancer vaccines and inhibitors of myeloid-derived suppressor cells(MDSCs). The company's lead candidate is IFx-2.0 personalized cancer vaccine involves a simple injection into a patient’s tumor of a small amount of pDNA that encodes for an immunogenic bacterial protein which gets expressed on the surface of the patient’s tumor.
- Oct 2025Unattributed$1.5M
- Jun 2025Unattributed$2.2M
- Dec 2023Unattributed$1.7M
- Jul 2022Unattributed$9.1M
#3
Series B · Miami, Florida · founded 2009 · 24 employees$35.8Mraised▾
Developer of an AI-powered skin cancer detection device. The company offers DermaSensor device that uses a combination of cutting-edge optical spectroscopy and artificial intelligence to promptly analyze suspicious skin lesions. The device shines light bursts on a lesion, captures scattered light spectra, and uses proprietary AI algorithms to assess malignancy risk for melanoma, basal cell carcinoma, and squamous cell carcinoma.
- Oct 2025Series B$16M
- Nov 2024Series B$8.9M
- Jun 2022Series B$10M
- Dec 2021Series A$8.5M
#4
Series A · Sunny Isles Beach, Florida · founded 2016 · 1 employees$12.9Mraised▾
Developer of a device for imaging diagnostics of cancer. It offers Time-Resolved Laser Induced Fluorescence Spectroscopy-based device to determine whether a brain lesion is benign or cancerous for resection of tumors.
- Jun 2025Series A$2M
- Mar 2023Series A$5.9M
- Apr 2021Seed$2.3M
- Sep 2016Seed$2.6M
#5
Series A · Doral, Florida · founded 2014 · 4 employees$3Mraised▾
Developer of molecular screening devices for the early detection of infectious diseases. The company develops a diversified portfolio of proprietary technologies and medical devices for the early identification of DNA and RNA virus-related pathologies. The product portfolio includes XytoTest and Anal test for cervical cancer, and HR-HPV DNA detection. Also, offers in-vitro diagnostic tests for the detection of HPV infections.
- Dec 2025Series A$250K
- Aug 2023Series A$6.9M
- Nov 2020Seed$3M
#6
Seed · Jupiter, Florida · founded 2020 · 8 employees$3Mraised▾
Developer of therapeutics for CNS-based disorders. The company has small molecule modulators which include MT-125 for different cancers, MT-110 for METH use disorders, and other substance use disorders.
- Aug 2025Grant (prize money)$4.5M
- Apr 2025Grant (prize money)$3M
- Mar 2025Grant (prize money)$1.5M
- Feb 2025Seed$3M
#7
Series A · Fort Lauderdale, Florida · founded 2020 · 13 employees$14.2Mraised▾
Developer of therapeutic vaccines for the treatment of cancer. The company has developed Syncrovax platform by utilizing intratumoral sync technology (IST) to design cancer therapies. The product pipeline includes NSC-IST, BRC-IST, OVN-IST, PRC-IST for the treatment of lung, breast, ovarian, and breast cancers.
- Dec 2024Series A$144.8M
- Nov 2022Series A$14.2M
#8
Series A · Tampa, Florida · founded 2011$5.2Mraised▾
Developing innovative therapies targeting cancer and liver disease. This pharmaceutical company is dedicated to supplying new therapies for defeating deadly cancers and related diseases, improving the quality of life for patients with unmet needs. Founded as a spinoff, the company focuses on moving its pipeline of targeted radio-therapy, small molecule, and peptide-based drug compounds efficiently through the clinic to achieve rapid regulatory approval and patient access. Their research and development efforts are centered on novel therapies targeting aggressive cancers and liver disease. The company operates with a team of pharmaceutical scientists, discoverers, researchers, biologists, chemists, and business developers, emphasizing collaboration and innovation in drug discovery and development.
- Mar 2025Grant (prize money)$2.6M
- Feb 2025Grant (prize money)$2.6M
- Feb 2016Series A—
- Feb 2013Seed—
#9
Public · Tampa, Florida · founded 1996 · 5 employees$87.3Mraised▾
Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health. Its lead drug AG013 is a live biotherapeutic candidate formulated as oral rinsing solution to deliver the therapeutic molecule Trefoil Factor 1 (TFF1) to the mucosal tissues in the oral cavity.
- Aug 2023Post IPO$850K
- Oct 2021Grant (prize money)$250K
- Aug 2021Grant (prize money)$256.7K
- Feb 2021Post IPO$22M
#10
Public · Fort Myers, Florida · founded 2002 · 2100 employees$445.5Mraised▾
Provider of cancer genetic diagnostic services. The company operates a network of cancer-focused testing labs, which is engaged in providing testing services to pathologists, oncologists, and other laboratories. The company provides services for cancer cytogenetics, hematologic and solid tumor FISH testing, 10-color flow cytometry, and nearly 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry.
- Jan 2021Post IPO$345M
- Jun 2019Conventional Debt$100M
- Mar 2009Post IPO$500K
#11
Seed · Ormond Beach, Florida · founded 2024$1.9Mraised▾
Developer of autologous natural killer (NK) cell therapies for cancer. These therapies are designed to be infused without lymphodepletion, broadening patient access and enabling convenient re-infusions. The approach aims for deeper, longer-lasting remissions by leveraging the intrinsic safety of NK cells and allowing them to cooperate with a fully intact host immune system. The company's pipeline focuses on minimal residual disease and enhancing antibody-dependent cellular cytotoxicity.
- Oct 2024Seed$500.5K
- Sep 2024Seed$750.5K
- Aug 2024Seed$649K
- Jun 2024Seed—
#12
Series A · Tampa, Florida · founded 2018 · 20 employees$30Mraised▾
Developer of next-generation immunotherapy products. The lead product AlloStim is a bioengineered, non-genetically altered CD4+ Th1-like memory cell with anti-CD3/anti-CD28 coated microbead that has potent immunomodulatory properties and causes the down-regulation of checkpoint inhibitor molecules, such as PD-1/L1 and CTLA4. Chaperone Rich Cell Lysate are heat shock proteins purified from a lysed tumor or virally infected cells which preserve the chaperoned peptides that contain tumor neoantigens. The company also developed immunomodulatory vaccines that affect the immune system and provides immune counter-measures to prevent tumors and infected cells.
- Oct 2022Series A$20M
- Dec 2021Series A$10M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology in Florida is moving
A read on the academic research around Oncology in Florida — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 356 papers.
- Mayo Clinic in Florida130
- University of Florida96
- University of South Florida60
- Florida College20
- Florida State University17
- Tumor microenvironment3→53
- Immune system3→36
- Cancer research3→33
- Breast cancer1→5
- Transcriptome1→3
- Tumor microenvironment5→99
- Immune system1→72
- Cancer research4→63
- Immunotherapy1→41
- Cancer2→25
- Cancer1→18
- Tumor microenvironment1→16
- Breast cancer1→5
- Cancer research1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.